2020
DOI: 10.1038/s41380-020-00933-x
|View full text |Cite
|
Sign up to set email alerts
|

Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?

Abstract: A consensus has yet to emerge whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disorder (OCD) can be considered an established therapy. In 2014, the World Society for Stereotactic and Functional Neurosurgery (WSSFN) published consensus guidelines stating that a therapy becomes established when “at least two blinded randomized controlled clinical trials from two different groups of researchers are published, both reporting an acceptable risk-benefit ratio, at least comparable w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
49
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

3
7

Authors

Journals

citations
Cited by 78 publications
(49 citation statements)
references
References 19 publications
0
49
0
Order By: Relevance
“…Deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD) can be an effective treatment for severely affected and treatment-refractory cases (1-3) but is still not considered a fully-established therapy (4). This is at least in part due to uncertainty about the precise brain networks to modulate for optimal treatment response.…”
Section: Introductionmentioning
confidence: 99%
“…Deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD) can be an effective treatment for severely affected and treatment-refractory cases (1-3) but is still not considered a fully-established therapy (4). This is at least in part due to uncertainty about the precise brain networks to modulate for optimal treatment response.…”
Section: Introductionmentioning
confidence: 99%
“…Deep brain stimulation (DBS) is an FDA-approved therapy for essential tremor ( Schuurman et al, 2000 ; Opri et al, 2020 ), Parkinson’s disease ( Rosin et al, 2011 ; Okun, 2012 ; Katz et al, 2015 ), idiopathic dystonia ( Kleiner-Fisman et al, 2007 ; Elkaim et al, 2019 ), and severe obsessive-compulsive disorder ( Figee et al, 2013 ; Wu et al, 2021 ) and exhibits potential therapeutic effects in the treatment of some other neurological and psychiatric disorders, such as depression ( Kennedy et al, 2011 ; Holtzheimer et al, 2017 ; Crowell et al, 2019 ), anorexia nervosa ( Lipsman et al, 2013 ; Lipsman et al, 2017 ), and addiction ( Luigjes et al, 2012 ; Creed et al, 2015 ). In addition, unlike pharmacotherapy, DBS has the advantages of adjusting stimulus parameters and starting and stopping stimulation at any time based on the condition of patients, and it also produces minimal side effects when used in clinical application ( Kringelbach et al, 2007 ).…”
Section: Introductionmentioning
confidence: 99%
“…A meta-analysis of 16 studies [ 18 ] found a 60% response rate for OCD overall, with most DBS targets overlapping in the VC/VS region. However, given these data, collaborative groups of investigators have indicated additional trials of DBS for OCD are needed [ 19 ].…”
Section: Introductionmentioning
confidence: 99%